Jun Zhao1, Li-li Zong, Ya-li Li. 1. Department of Obstetrics and Gynecology, General Hospital of PLA, Beijing 100853, China.
Abstract
OBJECTIVE: To explore the potential use of integrin av beta3 (Lm609) monoclonal antibody against ectopic lesion and microvessel angiogenesis of human endometriosis xenografts in SCID mice. METHODS: The endometrial tissues from endometriosis patients were inoculated subcutaneously into SCID mouse, which were treated with Lm609, an inhibitor of angiogenesis, twice a week, for 3 weeks. The mice were sacrificed and immunohistochemical staining was employed to determine the microvessel density (MVD) and expression of integrin av beta3 in the lesion tissues. RESULTS: Lm609 inhibited the growth of the ectopic lesion. The lesion weighted 0.82+/-0.09 g in the treated group versus 0.51+/-0.93 g in the control group (P<0.05). The MVDs of the treated and control groups were 31.2+/-4.4 and 14.4+/-1.8 respectively (P<0.05). CONCLUSION: Lm609 can inhibit the growth of ectopic lesion by reducing angiogenesis in SCID mouse.
OBJECTIVE: To explore the potential use of integrin av beta3 (Lm609) monoclonal antibody against ectopic lesion and microvessel angiogenesis of humanendometriosis xenografts in SCIDmice. METHODS: The endometrial tissues from endometriosispatients were inoculated subcutaneously into SCIDmouse, which were treated with Lm609, an inhibitor of angiogenesis, twice a week, for 3 weeks. The mice were sacrificed and immunohistochemical staining was employed to determine the microvessel density (MVD) and expression of integrin av beta3 in the lesion tissues. RESULTS:Lm609 inhibited the growth of the ectopic lesion. The lesion weighted 0.82+/-0.09 g in the treated group versus 0.51+/-0.93 g in the control group (P<0.05). The MVDs of the treated and control groups were 31.2+/-4.4 and 14.4+/-1.8 respectively (P<0.05). CONCLUSION:Lm609 can inhibit the growth of ectopic lesion by reducing angiogenesis in SCIDmouse.